A Minimal Clinically Important Difference for CAMPHOR in Idiopathic Pulmonary Arterial Hypertension
K. Bunclark (Cambridge (Cambridgeshire), United Kingdom), N. Doughty (Cambridge (Cambridgeshire), United Kingdom), A. Michael (Cambridge (Cambridgeshire), United Kingdom), N. Abraham (Cambridge (Cambridgeshire), United Kingdom), S. Ali (Cambridge (Cambridgeshire), United Kingdom), J. Cannon (Cambridge (Cambridgeshire), United Kingdom), K. Sheares (Cambridge (Cambridgeshire), United Kingdom), N. Speed (Cambridge (Cambridgeshire), United Kingdom), D. Taboada (Cambridge (Cambridgeshire), United Kingdom), M. Toshner (Cambridge (Cambridgeshire), United Kingdom), J. Pepke-Zaba (Cambridge (Cambridgeshire), United Kingdom)
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Bunclark (Cambridge (Cambridgeshire), United Kingdom), N. Doughty (Cambridge (Cambridgeshire), United Kingdom), A. Michael (Cambridge (Cambridgeshire), United Kingdom), N. Abraham (Cambridge (Cambridgeshire), United Kingdom), S. Ali (Cambridge (Cambridgeshire), United Kingdom), J. Cannon (Cambridge (Cambridgeshire), United Kingdom), K. Sheares (Cambridge (Cambridgeshire), United Kingdom), N. Speed (Cambridge (Cambridgeshire), United Kingdom), D. Taboada (Cambridge (Cambridgeshire), United Kingdom), M. Toshner (Cambridge (Cambridgeshire), United Kingdom), J. Pepke-Zaba (Cambridge (Cambridgeshire), United Kingdom). A Minimal Clinically Important Difference for CAMPHOR in Idiopathic Pulmonary Arterial Hypertension. 1517
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: